Evogene Net Interest Income from 2010 to 2026

EVGN Stock  USD 1.08  0.02  1.82%   
Evogene Net Interest Income yearly trend continues to be very stable with very little volatility. Net Interest Income is likely to grow to about 488.1 K this year. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2019-03-31
Previous Quarter
-393 K
Current Value
12 K
Quarterly Volatility
760.6 K
 
Covid
 
Interest Hikes
Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.5 M, Interest Expense of 201.5 K or Selling General Administrative of 6 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 54.52. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.
  
Build AI portfolio with Evogene Stock
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
Evaluating Evogene's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Evogene's fundamental strength.

Latest Evogene's Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of Evogene over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Evogene's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evogene's overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Evogene Net Interest Income Regression Statistics

Arithmetic Mean1,165,717
Geometric Mean1,326,493
Coefficient Of Variation129.48
Mean Deviation1,193,156
Median1,996,000
Standard Deviation1,509,343
Sample Variance2.3T
Range5.6M
R-Value(0.57)
Mean Square Error1.6T
R-Squared0.33
Significance0.02
Slope(170,489)
Total Sum of Squares36.4T

Evogene Net Interest Income History

2026488.1 K
2025368.1 K
2024409 K
20232.8 M
2022-2.8 M
2021521 K
2020-1.4 M

About Evogene Financial Statements

Evogene investors utilize fundamental indicators, such as Net Interest Income, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Interest Income368.1 K488.1 K

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

  0.63EDIT Editas MedicinePairCorr

Moving against Evogene Stock

  0.75DSGN Design TherapeuticsPairCorr
  0.63IMMP Immutep Ltd ADRPairCorr
  0.52KYTX Kyverna TherapeuticsPairCorr
  0.51ENGN enGene Holdings CommonPairCorr
  0.3463E ONWARD MEDICAL BVPairCorr
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Evogene diversify its offerings? Factors like these will boost the valuation of Evogene. Projected growth potential of Evogene fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Evogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.10)
Revenue Per Share
1.084
Quarterly Revenue Growth
(0.83)
Return On Assets
(0.31)
Return On Equity
(0.71)
Investors evaluate Evogene using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evogene's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Evogene's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evogene's market price signifies the transaction level at which participants voluntarily complete trades.